BioRestorative Therapies, Inc.BRTXEarnings & Financial Report
BioRestorative Therapies, Inc. is a clinical-stage biotechnology company focused on developing innovative regenerative medicine therapies. Its core pipeline includes candidate treatments for chronic lower back pain, metabolic disorders and other unmet medical needs, primarily serving markets in North America as it advances novel cell-based therapeutic candidates through clinical trials.
BRTX Q4 FY2025 Key Financial Metrics
Revenue
$19.6K
Gross Profit
$18.0K
Operating Profit
N/A
Net Profit
N/A
Gross Margin
91.7%
Operating Margin
N/A
Net Margin
N/A
YoY Growth
-54.7%
BioRestorative Therapies, Inc. Q4 FY2025 Financial Summary
BioRestorative Therapies, Inc. reported revenue of $19.6K (down 54.7% YoY) for Q4 FY2025, with a net profit of N/A (down 96.0% YoY) (N/A margin). Cost of goods sold was $1.6K.
Key Financial Metrics
| Total Revenue | $19.6K |
|---|---|
| Net Profit | N/A |
| Gross Margin | 91.7% |
| Operating Margin | N/A |
| Report Period | Q4 FY2025 |
BioRestorative Therapies, Inc. Annual Revenue by Year
BioRestorative Therapies, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $359.7K).
BioRestorative Therapies, Inc. Quarterly Revenue & Net Profit History
BioRestorative Therapies, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $19.6K | -54.7% | N/A | N/A |
| Q3 FY2025 | $11.8K | -94.9% | $-3.0M | -25748.1% |
| Q2 FY2025 | $303.3K | +240.4% | $-2.7M | -875.8% |
| Q1 FY2025 | $25.0K | -28.6% | $-5.3M | -21359.2% |
| Q4 FY2024 | $43.3K | +124.4% | $-1.6M | -3778.6% |
| Q3 FY2024 | $233.6K | +660.9% | $-1.1M | -467.2% |
| Q2 FY2024 | $89.1K | +38.1% | $-4.0M | -4521.4% |
| Q1 FY2024 | $35.0K | +11.8% | $-2.2M | -6352.2% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $35000 | $89100 | $233600 | $43300 | $25000 | $303300 | $11800 | $19600 |
| YoY Growth | 11.8% | 38.1% | 660.9% | 124.4% | -28.6% | 240.4% | -94.9% | -54.7% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $18.0M | $16.1M | $14.6M | $12.3M | $10.3M | $8.5M | $5.6M | $4.1M |
| Liabilities | $3.4M | $5.3M | $4.6M | $3.7M | $4.2M | $3.7M | $3.4M | $3.7M |
| Equity | $14.5M | $10.8M | $10.0M | $8.5M | $6.1M | $4.8M | $2.2M | $356744 |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-2.3M | $-1.9M | $-1.7M | $-2.3M | $-2.8M | $-2.7M | $-2.9M | $-10.8M |